Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

14 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS2RpY1KGR? MoXmTWM2OD13LkewOUAh|ryPIB?= MVqxPFU2QTZzMx?=
KP6.3 M4fhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;sOEBl MmexTWM2OD1zMD60Nlgh|ryPIB?= NXnkSIs6OTh3NUm2NVM>
KP7.7 NEPsT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILU[Gs1KGR? MnzDTWM2OD13NzDuUUA> MWKxPFU2QTZzMx?=
KB2P3.4 NVS3[nJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDzVW1rPCCm Mm\LTWM2OD1zMkSgUUA> MVuxPFU2QTZzMx?=
KB2P1.21 M3jPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQOEBl M2O0PGlEPTB;OEmwO{BvVSB? NHn5UVEyQDV3OU[xNy=>
U373-MG NX\r[Wc3S3m2b4TvfIlkKEG|c3H5 Mn3mNUDPxE1i MXOyOEBp Mm\oTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NUHyU|FMOTh7NUS3NVI>
T98G NHXMO|ZEgXSxdH;4bYMhSXO|YYm= NGqydHoyKM7:TTC= NHX2eHIzPCCq MnP4TY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? MnTlNVg6PTR5MUK=
U87-MG M37jZmN6fG:2b4jpZ{BCe3OjeR?= MVSxJO69VSB? NVjHc4g4OjRiaB?= M1jRdmlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? MYKxPFk2PDdzMh?=
UVW NHu2SZVEgXSxdH;4bYMhSXO|YYm= M{m5VFUxOCCwTR?= NHzLeoIzPCCq M1;L[Wlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? MkXTNVg6PTR5MUK=
HeLa M2jPWGZ2dmO2aX;uJGF{e2G7 NFTwOGg2ODBibl2= NW\ZTnFmPCCq Mon5R4F2e2W|IHGgcY9l\XO2IHTlcIF6KGmwIILlbo9qdmmwZzDv[kBz[WSrYYTpc44ucW6mdXPl[EBFVkFiYoLlZYt{ M{P4e|E5QTV2N{Gy
HeLa MWrGeY5kfGmxbjDBd5NigQ>? MlvmNUDPxE1i Mk[zNlQhcA>? NYPheWdHTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= NEiwTIsyQDl3NEexNi=>
T98G NW\yfIFnTnWwY4Tpc44hSXO|YYm= NEfKfWgyKM7:TTC= MmjnNlQhcA>? Mo\xSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? NVXVU3o4OTh7NUS3NVI>
L3 M1:zfWN6fG:2b4jpZ{BCe3OjeR?= M3jjdlUh|ryPIB?= MnrVPVYhcA>? NHz2cWVFVVOR NYLMbFZPW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MXuyNFEzPDR3OR?=
Granta-519 M2e5NmN6fG:2b4jpZ{BCe3OjeR?= NV3SZ28zPSEQvF2g M1H5WFk3KGh? MYDEUXNQ MlLWV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NUK0ZnpiOjBzMkS0OVk>
BT NID1NWVEgXSxdH;4bYMhSXO|YYm= NX7OfHVPPSEQvF2g NVXlOm03QTZiaB?= NID5U5ZFVVOR Mn3LV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? M1S3flIxOTJ2NEW5
UPN2 NIrjUYtEgXSxdH;4bYMhSXO|YYm= MkXyOUDPxE1i M{PhOFk3KGh? NH7XOGlFVVOR M1rObXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NE[ySIgzODF{NES1PS=>
HBL-2 Mo\ER5l1d3SxeHnjJGF{e2G7 NF;LfIg2KM7:TTC= MornPVYhcA>? NX:5U5dqTE2VTx?= MlXtV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NIXHOlYzODF{NES1PS=>
JVM-2 NVHJTpVpS3m2b4TvfIlkKEG|c3H5 MXy1JO69VSB? NX3C[5dXQTZiaB?= NF3lVJBFVVOR NFT0Z|FUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MoLXNlAyOjR2NUm=
Z138 M4Lx[GN6fG:2b4jpZ{BCe3OjeR?= NEDFNHY2KM7:TTC= MkXXPVYhcA>? M4LTUGROW09? NGq0V2hUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MVSyNFEzPDR3OR?=
RWPE NX[xNI81UW64YYPpeoUhSXO|YYm= MkjHNlUh|ryP NHLGc|M1QCCq Mn:5SG1UVw>? MkDXV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NU\mRVl5OjF3N{W4OlU>
VCaP M33Pd2lvfmG|aY\lJGF{e2G7 MnLDNlUh|ryP M17LflQ5KGh? NXP2Zok2TE2VTx?= MVfTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;u MofTNlE2PzV6NkW=
Mouse H2AX−/− ES Cells NHjZc4NEgXSxdH;4bYMhSXO|YYm= NHTGTngzNjVizszN M{TrS|IxKGh? M2Gxc3Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> NWTkT4Y3OjN|NUW0PFk>
Mouse ATM−/− ES Cells M2fZV2N6fG:2b4jpZ{BCe3OjeR?= MYGyMlUh|ryP M2TCfVIxKGh? MojwV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs M4OxbFI{OzV3NEi5
H1650 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj1NlAh|ryP M2DnR|E1PCCq MlnOTWM2OD1zNT60O{DPxE1? M2WwV|I{OjN7OEC5
H1650PTEN+ NUDlSmZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIWGYzOCEQvF2= M2PQTFE1PCCq MWfJR|UxRTVyLkizJO69VQ>? NYX2dFF{OjN{M{m4NFk>
PC-9 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6Z4czOCEQvF2= MkXHNVQ1KGh? M1\KcWlEPTB;NT64PEDPxE1? NVLTN4x[OjN{M{m4NFk>
PC-9PTEN− NXjXbmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrEOG1vOjBizszN MojlNVQ1KGh? MX7JR|UxRTZwNUKg{txO M2fPflI{OjN7OEC5
MDA-MB-231 NGe1bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjEOUBl[Xl? NVLmenVsUUN3ME22Mlkh|ryP MofLNlM4PjB2OU[=
MDA-MB-468 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXG1JIRigQ>? MnHSTWM2OD13LkCg{txO MWKyN|c3ODR7Nh?=
BT20 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzSppsPSCmYYm= M1Kwb2lEPTB;Nz63JO69VQ>? NVP6N|k6OjN5NkC0PVY>
HCC1143 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPJdY9DPSCmYYm= NX;yPWprUUN3ME2xNU4yKM7:TR?= M{L2UFI{PzZyNEm2
HCC1937 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfBWnBsPSCmYYm= MYnJR|UxRTF{Lk[g{txO MmLoNlM4PjB2OU[=
Hs578t Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nMclUh\GG7 Ml;PTWM2OD13Lk[g{txO NXjXNmw{OjN5NkC0PVY>
Hs578t(si) NEfn[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHpSWM2KGSjeR?= M1:1WmlEPTB;Nz61JO69VQ>? M2DBcVI{PzZyNEm2
BT474 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzBOUBl[Xl? MmPJTWM2OD1zOT64JO69VQ>? M33MeVI{PzZyNEm2
JIMT1 NVryeGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW1JIRigQ>? MUXJR|UxRTdwNzFOwG0> Mk[2NlM4PjB2OU[=
SKBR3 MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vTVUh\GG7 M3W2eGlEPTB;MUGuNUDPxE1? M3jPfFI{PzZyNEm2
SUM159 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrOTpBDPSCmYYm= MW\JR|UxRTRwMjFOwG0> MWGyN|c3ODR7Nh?=
CAMA1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Sb|Q2KGSjeR?= M36xWGlEPTB;MUWuPEDPxE1? M{fTbFI{PzZyNEm2
MCF7 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfhOUBl[Xl? M2\hcGlEPTB;NT64JO69VQ>? NGHpVW4zOzd4MES5Oi=>
T47D MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;o[HVFPSCmYYm= NHXTc5hKSzVyPUmuOkDPxE1? NGq2XokzOzd4MES5Oi=>
HCT116 NYHCXIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjweFFJOTByIN88US=> Mni5OFghcA>? M2LlVWROW09? MWnJR|UxRTJwNTFOwG0h MXWyOFU4Pzl2MR?=
SW1116 M1HIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[0SVExOCEQvF2= NXKzbIxxPDhiaB?= NEO5PHBFVVOR M2\DTWlEPTB;MUCwJO69VQ>? M3z2Z|I1PTd5OUSx
HT29 NVHMN5Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNFAh|ryP M1HOcFQ5KGh? NGr3XplFVVOR MVfJR|UxRTF2Lkeg{txO M{H0WFI1PTd5OUSx
LoVo NFvvcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iyeFExOCEQvF2= MkfMOFghcA>? M4LCd2ROW09? MXHJR|UxRTF|LkSg{txO Ml\VNlQ2Pzd7NEG=
HCT-15 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwNG4yODBizszN NFjySXI1QCCq M1HCXWROW09? MmTmTWM2OD1zMDFOwG0> MlPSNlQ2Pzd7NEG=
SW48 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnxWIN3OTByIN88US=> M4jEU|Q5KGh? MmHISG1UVw>? M3XaV2lEPTB;OT61JO69VQ>? MUKyOFU4Pzl2MR?=
C-1 NFfG[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNFAh|ryP M{DWd|Q5KGh? NYDjT|h3TE2VTx?= MYfJR|UxRTdwNjFOwG0> M2HJcVI1PTd5OUSx
RKO NFnOeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUixNFAh|ryP M370blQ5KGh? NXP2eFM5TE2VTx?= NUXJZmRwUUN3ME21Mlkh|ryP MVuyOFU4Pzl2MR?=
HCT116 NUHOfG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexNFAh|ryP MXy0PEBp M2mwdGROW09? M1XZcnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M120[lI1PTd5OUSx
SW1116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNFAh|ryP MWK0PEBp M{PYXWROW09? NEHyTlVRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MWmyOFU4Pzl2MR?=
HT29 M{ewTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLKOpc5OTByIN88US=> NVH3bJRXPDhiaB?= Mon1SG1UVw>? NGPwSJVRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NX7Z[JQ3OjR3N{e5OFE>
LoVo NYTKcWg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfKRXRGOTByIN88US=> NUn1UYlPPDhiaB?= NYnkZo1bTE2VTx?= MYHQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NGLGZ3gzPDV5N{m0NS=>
SW48 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO0WYZmOTByIN88US=> NITlfZA1QCCq MV7EUXNQ NFroemtRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NHfx[pkzPDV5N{m0NS=>
C-1 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUixNFAh|ryP M1X4NFQ5KGh? MkDhSG1UVw>? MlLRVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MnH4NlQ2Pzd7NEG=
RKO NUK5[VNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNFAh|ryP NYjtWXA5PDhiaB?= M2HUVGROW09? NXG2V4piWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MYWyOFU4Pzl2MR?=
HCT116 NGTzW5RHfW6ldHnvckBCe3OjeR?= M4TZO|ExKG6P MVuxNkBp MUTEUXNQ MXHJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? MkTaNlQ2Pzd7NEG=
HT29 MWLGeY5kfGmxbjDBd5NigQ>? NXLUOZQ3OTBibl2= MmPCNVIhcA>? NHHFcG1FVVOR MmToTY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NGDVXI8zPDV5N{m0NS=>
TE-6 MmDiSpVv[3Srb36gRZN{[Xl? NGG1UZI2KM7:TTC= NYGyR21kOTJiaB?= NW\QT4xqTE2VTx?= M{DabGlv\HWlZYOgS|IwVSCjcoLld5Q> MWqyOFIyQTF4NB?=
TE-6 MVLGeY5kfGmxbjDBd5NigQ>? NEPtO3k2KM7:TTC= MmnLNlQhcA>? MkG5SG1UVw>? NV7Gc3g3UW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= Mn3uNlQzOTlzNkS=
Hep3B NYn1NpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37zVlQxKM7:TTC= MVW3NkBp M3PtWWROW09? Mm\6V5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> NGOyU2wzPTB5Mke1Ni=>
Huh7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n2ZVQxKM7:TTC= M4PvRlczKGh? NELmbVNFVVOR NHrOdHlUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? MXOyOVA4Ojd3Mh?=
Hep3B M{TCd2Z2dmO2aX;uJGF{e2G7 NGnvXpA1OCEQvF2g NHXxOWszPCCq M3nJZ2ROW09? MUXJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? Mn7PNlUxPzJ5NUK=
Huh7 NF7ZenVHfW6ldHnvckBCe3OjeR?= Ml\wOFAh|ryPIB?= NGrTN|YzPCCq Moj3SG1UVw>? MVLJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NFTs[nYzPTB5Mke1Ni=>
Hep3B MY\GeY5kfGmxbjDBd5NigQ>? NYraSVdLPDBizszNJC=> MnHWNlQhcA>? NIXpe4FFVVOR NWnNRo81UW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR M2[4[VI2ODd{N{Wy
Huh7 NUnKV5hGTnWwY4Tpc44hSXO|YYm= MXi0NEDPxE1i Mn2xNlQhcA>? MUXEUXNQ MmjaTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MW[yOVA4Ojd3Mh?=
SGC-7901 NF3DUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKzNOKh|ryP M{nlWlQ5KGh? MnXySG1UVw>? NGTkdYhDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MVyyOVc3PzB5Nh?=
COLO-800 M{j0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDiZmlnUUN3ME2wMlQ1OTZ2IN88US=> M3vpRXNCVkeHUh?=
EoL-1- M3;sfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjXdHpjUUN3ME2wMlU3PDR4IN88US=> NHvqe|FUSU6JRWK=
NCI-H209 NXL0OFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwOUG1OVYh|ryP M1Loc3NCVkeHUh?=
ES1 M1POdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\lbmtGUUN3ME2xMlEyPDB6IN88US=> NYnpcYNbW0GQR1XS
NKM-1 M2O2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;5TWM2OD1zLkK1N|Q4KM7:TR?= MlzxV2FPT0WU
NTERA-S-cl-D1 NXnsNnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H4Z2lEPTB;MT6zN|M1OSEQvF2= NXnXepRSW0GQR1XS
MHH-ES-1 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr0fnRKSzVyPUGuOlIxPjdizszN NWLuRldWW0GQR1XS
ES8 NVLVVo9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjoPWc5UUN3ME2xMlczPDF2IN88US=> MXjTRW5ITVJ?
NCI-H720 M3XDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n6TGlEPTB;Mj6yNFY6QSEQvF2= MmLlV2FPT0WU
EW-3 NVK1SHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHBTWM2OD1{LkK3OVM1KM7:TR?= NIPBN|hUSU6JRWK=
D-566MG NYrVeVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfLRllKSzVyPUKuOFQ2PjhizszN NWHzTo9[W0GQR1XS
697 NY\xd4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJwOESxO|Mh|ryP MWHTRW5ITVJ?
ES5 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwOEixPFkh|ryP NVPEOIJ[W0GQR1XS
COLO-684 NFuzeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2yPFdNUUN3ME2zMlUyPjl4IN88US=> MWDTRW5ITVJ?
ML-2 NIq0dW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDBTWM2OD1|Lk[wNFU5KM7:TR?= MVfTRW5ITVJ?
MC-IXC NU[3[2xoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm5Zox5UUN3ME2zMlY{Ozl|IN88US=> M1X0dnNCVkeHUh?=
DB NX\TWnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjET3lKSzVyPUOuOlU1PDhizszN M4C2WHNCVkeHUh?=
HCC2218 NYnOeY94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXXR4VsUUN3ME2zMlc{OTB|IN88US=> M{j0OHNCVkeHUh?=
NCI-H510A NYizXXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPRTWM2OD1|LkiyO|I1KM7:TR?= M4P4bXNCVkeHUh?=
NCI-H526 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWxfZM5UUN3ME2zMlg3QTV6IN88US=> NW\odo9YW0GQR1XS
MV-4-11 M1;CWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXTdmRyUUN3ME20MlE{OzN2IN88US=> M4LEO3NCVkeHUh?=
PA-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4[WVKSzVyPUSuNlUzQSEQvF2= Mn7aV2FPT0WU
EW-22 M2[wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWwTmtNUUN3ME20MlM2QDZizszN NVqyZ485W0GQR1XS
KASUMI-1 M2OwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjKTWM2OD12LkSwNVA6KM7:TR?= MVTTRW5ITVJ?
LU-139 NWfVb3ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\iXIc3UUN3ME20Mlc2QDJ7IN88US=> M3fh[XNCVkeHUh?=
SBC-1 NGj2NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr0TWM2OD12LkiwPVA5KM7:TR?= M2jCZnNCVkeHUh?=
H4 NIPtZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDqTWM2OD12Lki5OFQ{KM7:TR?= MUDTRW5ITVJ?
EW-11 NXPpWlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXsNJRKSzVyPUWuNFgxPzJizszN NXXrWXltW0GQR1XS
NBsusSR NIjWcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPKTWM2OD13LkGyNFU2KM7:TR?= M1S5UHNCVkeHUh?=
RPMI-8226 M{\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDBTWM2OD13LkG1NlQ1KM7:TR?= M{D4TXNCVkeHUh?=
DEL NIDQNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwMkCwNFYh|ryP MX7TRW5ITVJ?
ES4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwNUGzPFkh|ryP MVXTRW5ITVJ?
GCT Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD13LkW2PFU3KM7:TR?= NITPPXhUSU6JRWK=
NCI-H1048 M2TEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDZ[41KUUN3ME21Mlk4Ojd|IN88US=> NVjW[25uW0GQR1XS
NCI-SNU-1 M13qTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwMEKyJO69VQ>? MUnTRW5ITVJ?
ES7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O5R2lEPTB;Nj6wN|U4PyEQvF2= NGrXPVlUSU6JRWK=
SW982 M3\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwMEmxN|ch|ryP NW[2VZM1W0GQR1XS
L-363 M1jSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTZwM{O5O|Qh|ryP MXHTRW5ITVJ?
HT-1080 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn24TWM2OD14LkS5Olg{KM7:TR?= NWGxcFBIW0GQR1XS
HAL-01 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDTNohKSzVyPU[uOVExQSEQvF2= MmS3V2FPT0WU
NB14 M4jlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrVd|JKSzVyPU[uOlQxOzlizszN MUXTRW5ITVJ?
EW-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL1OlJNUUN3ME22Mlc4PDJ2IN88US=> MYHTRW5ITVJ?
NY NYfl[HhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7jTWM2OD14Lkm0OlA2KM7:TR?= MV\TRW5ITVJ?
NCI-SNU-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPNTWM2OD15LkGwOFM{KM7:TR?= MXjTRW5ITVJ?
MS-1 NVjQeZg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LGdmlEPTB;Nz6xO|Q6PCEQvF2= NI\TTGhUSU6JRWK=
EW-16 M1XJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDuS|FKSzVyPUeuN|E5PjFizszN NWLj[lFNW0GQR1XS
LU-65 M4K1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C1UWlEPTB;Nz60PFQyPyEQvF2= MoTRV2FPT0WU
HGC-27 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTdwN{KxO|Mh|ryP MlO4V2FPT0WU
CTB-1 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTdwN{[xO|Uh|ryP NYHEcoF6W0GQR1XS
5637 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW4cGZKSzVyPUeuPVI5PiEQvF2= MnnhV2FPT0WU
U251 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzRTWM2OD15Lkm0NFE3KM7:TR?= M3;BfnNCVkeHUh?=
HOS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzGTWM2OD16LkKzNFA4KM7:TR?= MYHTRW5ITVJ?
DOHH-2 NGnoVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRThwMkO1PEDPxE1? MVnTRW5ITVJ?
EW-1 NFzkdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\y[IhEUUN3ME24MlMxODh6IN88US=> NV62R4p[W0GQR1XS
BV-173 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ocJdEUUN3ME24MlU2PTRizszN MWDTRW5ITVJ?
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXUTWM2OD16Lk[4PVg5KM7:TR?= MXfTRW5ITVJ?
NB69 NGTieIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fGTGlEPTB;OD63NFkzOSEQvF2= NGrxbmZUSU6JRWK=
NCI-H69 NUDkO5EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fufWlEPTB;OT65NFk3OSEQvF2= NVnrc4NIW0GQR1XS
RS4-11 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFzLkKyNFgh|ryP NES4ZpVUSU6JRWK=
ONS-76 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFzLkK5OFch|ryP NIHuZYxUSU6JRWK=
SF539 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDyOIVUUUN3ME2xNU41QDh7IN88US=> NWjL[5JGW0GQR1XS
HuO-3N1 NVfrW3huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnlVVNKSzVyPUGxMlU4QTZizszN M4HCVnNCVkeHUh?=
NCI-H1651 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPIVHJKSzVyPUGyMlMyOTVizszN NXnvR4prW0GQR1XS
KARPAS-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPTVJluUUN3ME2xNk4{PzZizszN NWX0fWNxW0GQR1XS
SK-NEP-1 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TNOGlEPTB;MUKuOFYxQSEQvF2= MVrTRW5ITVJ?
LAMA-84 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrudI1KSzVyPUGzMlExQTVizszN MV;TRW5ITVJ?
NCI-H1155 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOW3hKSzVyPUGzMlI5PTZizszN MkTJV2FPT0WU
CTV-1 M1v2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDyUI9XUUN3ME2xN{41PDVizszN NXn1XGNHW0GQR1XS
QIMR-WIL NYXWWlF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm5WmVZUUN3ME2xN{44QDF2IN88US=> M1TUN3NCVkeHUh?=
H9 NGf1OZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvuW5VKSzVyPUGzMlg1PzVizszN MlKyV2FPT0WU
SK-MEL-1 NXLZU4xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHiS|llUUN3ME2xN{46OzR5IN88US=> MVzTRW5ITVJ?
HD-MY-Z MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoTmlEPTB;MUSuNFY{PyEQvF2= NXW3[ItEW0GQR1XS
TI-73 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDsT2hKSzVyPUG0MlI{PTZizszN MYfTRW5ITVJ?
JVM-3 M4jmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF3LkW3NVYh|ryP MX3TRW5ITVJ?
D-247MG MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP5TWM2OD1zNT61PVMh|ryP NF;h[ZVUSU6JRWK=
VA-ES-BJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF3Lk[wPVch|ryP NF\PZnRUSU6JRWK=
NOS-1 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD2NXY{UUN3ME2xOU43PTJ{IN88US=> M4DvcnNCVkeHUh?=
MOLT-4 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGzO|JKSzVyPUG2Mlc2OiEQvF2= MmD1V2FPT0WU
Mo-T M{LMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF5LkC4OFkh|ryP MWnTRW5ITVJ?
NCI-H1770 M{D2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H2dmlEPTB;MUeuNVU1OyEQvF2= NV3JboJXW0GQR1XS
COLO-320-HSR M{O4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxWIhOUUN3ME2xO{4yQDJ5IN88US=> MWjTRW5ITVJ?
TE-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fvbWlEPTB;MUeuO|A2PCEQvF2= MUXTRW5ITVJ?
NCI-H82 M36we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF5Lki3Nlgh|ryP MWDTRW5ITVJ?
NEC8 NVjicYlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF6LkGzNVYh|ryP NGnKfJdUSU6JRWK=
HSC-3 NI\vNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF6Lke0NVQh|ryP NXLTbmlwW0GQR1XS
NCI-H1092 NHPpO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHkcnhMUUN3ME2xPE44PTl3IN88US=> M17qTHNCVkeHUh?=
NCI-H292 M3LvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF7LkC0PFkh|ryP NUPrRpZ5W0GQR1XS
L-428 NXXVOm03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHQTWM2OD1zOT61OVkh|ryP MXjTRW5ITVJ?
LU-134-A NGnobIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLNTWM2OD1zOT61O|Ih|ryP M3;WfnNCVkeHUh?=
GI-ME-N MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;NbGlEPTB;MUmuOVc1PyEQvF2= MoDUV2FPT0WU
ALL-PO M{\0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzYN|ZMUUN3ME2xPU42QTd{IN88US=> NXfHN3FGW0GQR1XS
D-283MED NWGz[4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjMU4FKSzVyPUG5MlkyPSEQvF2= M2OxenNCVkeHUh?=
D-423MG MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF7Lkm5Olch|ryP NVj6UWpPW0GQR1XS
CAKI-1 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TXZWlEPTB;MkCuNlIyQSEQvF2= Mn\UV2FPT0WU
ETK-1 M1HxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnewTWM2OD1{MD6yOlE2KM7:TR?= NGTlW5BUSU6JRWK=
G-402 NX3RZXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWex[JZUUUN3ME2yNE42OzN2IN88US=> M161[nNCVkeHUh?=
HL-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS0fGp2UUN3ME2yNU4yPjF|IN88US=> NHnqNYlUSU6JRWK=
A2058 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDsTWM2OD1{MT60OFc4KM7:TR?= MV\TRW5ITVJ?
CHP-212 NWj6SVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zseGlEPTB;MkGuPVA2OSEQvF2= Mo\aV2FPT0WU
KY821 NYezdZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhOWlEPTB;MkGuPVc2KM7:TR?= NGfaSFJUSU6JRWK=
TYK-nu Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPOU|ROUUN3ME2yNk4xPjVzIN88US=> NUj2Uot[W0GQR1XS
JVM-2 NYHJ[FBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPuO4dKSzVyPUKyMlI6QDNizszN MUHTRW5ITVJ?
KU812 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwfHM{UUN3ME2yNk44OzF{IN88US=> MW\TRW5ITVJ?
MKN28 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rI[WlEPTB;MkKuPVAyPSEQvF2= NHqyOWFUSU6JRWK=
ECC10 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzKfHpjUUN3ME2yN{44PDFizszN MorGV2FPT0WU
BHT-101 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;kb2dnUUN3ME2yOE4xODB6IN88US=> NWDBV3JiW0GQR1XS
DU-4475 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\vTWM2OD1{ND6zN|M4KM7:TR?= NXW0bVR3W0GQR1XS
769-P Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\2XIRMUUN3ME2yOE45PDZ4IN88US=> MmTyV2FPT0WU
HEC-1 M1e3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ3LkS0OUDPxE1? M2r5[3NCVkeHUh?=
MOLT-13 NVzCeFdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fxNmlEPTB;MkWuOVM{OSEQvF2= MoHqV2FPT0WU
8505C NYPUNoZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLXTWM2OD1{Nj60PVc4KM7:TR?= NVnmTIJGW0GQR1XS
GB-1 NVP6XHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4TWM2OD1{Nj63NVc3KM7:TR?= MnS0V2FPT0WU
SF126 NFr5WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfETWM2OD1{Nj63OlQ5KM7:TR?= MXfTRW5ITVJ?
A4-Fuk Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ5LkGyO|Eh|ryP MkTMV2FPT0WU
OVCAR-8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3t[4JKSzVyPUK3MlE2OzlizszN M2PaXHNCVkeHUh?=
NCI-H1304 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrL[JFoUUN3ME2yO{42PCEQvF2= NYGxUXBLW0GQR1XS
GR-ST M2T3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jqTGlEPTB;MkiuNFQ4KM7:TR?= Mn7kV2FPT0WU
G-401 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJ6LkWwPVYh|ryP MUjTRW5ITVJ?
LXF-289 NYi3TVZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ6LkW2OVEh|ryP M4jK[nNCVkeHUh?=
DBTRG-05MG MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTMTWM2OD1{OD65NlA1KM7:TR?= M4e0eXNCVkeHUh?=
YKG-1 NYTtRZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD1{OT64Olgh|ryP NUnhWWs4W0GQR1XS
GAMG M3W4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\KeZZKSzVyPUK5Mlk6OyEQvF2= MU\TRW5ITVJ?
HCT-116 NG\Gc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[3cG0zUUN3ME2zNE4xPTR6IN88US=> NFLjT3NUSU6JRWK=
S-117 M{PVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNzLkKyOVch|ryP MVLTRW5ITVJ?
NCI-H1693 NHfyeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzXnZKSzVyPUOzMlY2PDJizszN NWm2bJV[W0GQR1XS
A427 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTN|Lkm5O|Yh|ryP MU\TRW5ITVJ?
HT-29 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HzdGlEPTB;M{SuOlA{OiEQvF2= NHnvSZhUSU6JRWK=
P12-ICHIKAWA NF3SR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN2Lke0PVEh|ryP MlrYV2FPT0WU
CAL-51 NWC1b2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN3LkC3NFkh|ryP MoHtV2FPT0WU
Ramos-2G6-4C10 M{DWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHOTWM2OD1|NT6yOFI2KM7:TR?= M3jIW3NCVkeHUh?=
SCH M{OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuwTYJGUUN3ME2zOk41OTd2IN88US=> M2\oNnNCVkeHUh?=
SK-MEL-24 M2PNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjXO2E4UUN3ME2zOk46ODR2IN88US=> MWXTRW5ITVJ?
SW1573 M13BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnTUHdKSzVyPUO4MlczOTZizszN NVLjZ5h{W0GQR1XS
BALL-1 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTN7LkKxNlkh|ryP M4LyXXNCVkeHUh?=
BE-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3jNXdKSzVyPUO5MlMzQSEQvF2= NICyWXNUSU6JRWK=
GI-1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O0NmlEPTB;M{muPFY1PyEQvF2= NVm0TGRrW0GQR1XS
GOTO M2q2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTN7LkmxN|kh|ryP M2DL[3NCVkeHUh?=
A673 NWX0bYl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[xSWFKSzVyPUSxMlA{PDNizszN M2fxSnNCVkeHUh?=
KG-1 NGK3SFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPWU|lxUUN3ME20N{4{QTRizszN MmfkV2FPT0WU
GP5d MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe2UnFKSzVyPUS0MlA3PjZizszN Mn;HV2FPT0WU
MFM-223 NVLBcZF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DWN2lEPTB;NESuNVIzQCEQvF2= M3KwWnNCVkeHUh?=
OAW-42 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TNSmlEPTB;NESuNlY1OyEQvF2= NF7NdZlUSU6JRWK=
C8166 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPx[4hKSzVyPUS1MlA5OjJizszN Ml\0V2FPT0WU
LU-99A MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLLTWM2OD12Nj6xN|IzKM7:TR?= Mm\RV2FPT0WU
NCI-H23 M3fjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMZ2lEPTB;NE[uNVc5PSEQvF2= NFLy[4tUSU6JRWK=
HO-1-N-1 NYPIPHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5UItCUUN3ME20O{4xQTl6IN88US=> M4jlfHNCVkeHUh?=
A3-KAW NIn1ZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXUR5RKSzVyPUS3MlExODdizszN MW\TRW5ITVJ?
CGTH-W-1 NUWy[ZJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG5TWM2OD12Nz61NFY6KM7:TR?= MkHRV2FPT0WU
DJM-1 NV\UZWpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\UNIR3UUN3ME20O{42PDF|IN88US=> MVnTRW5ITVJ?
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTLS2dWUUN3ME20O{43OzV5IN88US=> NFvXNW1USU6JRWK=
BB30-HNC M3zLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGwWnlSUUN3ME20PE4{ODd{IN88US=> M2OxU3NCVkeHUh?=
T98G NUG4UW1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR6LkS2N|Mh|ryP NYT0fW1UW0GQR1XS
NCI-H1573 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\OR4RKSzVyPUS5MlQ1PjJizszN M3zWZnNCVkeHUh?=
MEG-01 NHXIelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR7Lke0NVEh|ryP M1TMVXNCVkeHUh?=
WM-115 M1HqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF30THJKSzVyPUS5MlkzOjJizszN M2rafHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID